Trial targeting tumours
A new device that targets hard-to-kill tumours is the focus of a research trial led by The Alfred's interventional radiology team.
COVID-19: Find out about our screening clinic - and note our current visitor restrictions
A new device that targets hard-to-kill tumours is the focus of a research trial led by The Alfred's interventional radiology team.
With the new model of a Vagal Nerve Stimulator (VNS), our neurology team can pre-program our epilepsy patients treatment months in advance - meaning they can visit the hospital less often.
Alfred Health staff are eagerly rolling up their sleeves as the health service assists with vaccinating frontline workers against COVID-19 this week.
Wishing you safe and happy holidays, from Alfred Health.
Our Mental and Addiction Health team have created a Psychological First Aid (PFA) course to equip our staff with the skills to help someone in distress.
Making up 80 per-cent of all brain tumours in adults, gliomas such as glioblastoma (GBM) are the most common and aggressive form of brain cancer. Killing more people under forty than any other cancer, a quarter of a million people die every year from these tumours – despite current treatment options the average survival for a GBM is only 14-15 months after diagnosis
Working in the intensive care unit (ICU) as a consultant and medical donation specialist, Dr Dashiell Gantner understands that at the end of a person’s life, knowing that their choices will be respected is very important.
The Alfred Heart and Lung Transplant team see the daily battles and the extraordinary journeys all our transplant patients face. Professor Andrew Taylor and Janelle McLean from this team, are by these patient’s side from their very first admission to their final follow up appointment.
As part of International Women’s Day (Sunday 8 March), Alfred Health will recognise the significant contribution of women at the organisation.
Smoke from the devastating bushfires is blanketing many parts of Victoria, including Melbourne.